CJ-023,423, a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 2, 2007, Pages 686-694

  Nakao, Kazunari ^a   Murase, Akio ^a   Ohshiro, Hiroyuki ^a   Okumura, Takako ^a   Taniguchi, Kana ^a   Murata, Yoko ^a   Masuda, Masatoshi ^a   Kato, Tomoki ^a   Okumura, Yoshiyuki ^a   Takada, Junji ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CJ 023423; CYCLIC AMP; N [[[2 [4 (2 ETHYL 4,6 DIMETHYL 1H IMIDAZO[4,5 C]PYRIDIN 1 YL)PHENYL]ETHYL]AMINO]CARBONYL] 4 METHYLBENZENESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E2; PROSTAGLANDIN EP4 RECEPTOR; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANALGESIC ACTIVITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR DISTRIBUTION; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG TOLERABILITY; EMBRYO; EXPERIMENTAL MODEL; EXPERIMENTAL RAT; HUMAN; HUMAN CELL; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; RAT; RECEPTOR BLOCKING; STATISTICAL SIGNIFICANCE;

ANALGESICS; ANIMALS; BINDING, COMPETITIVE; CARRAGEENAN; CELL LINE; CELLS, CULTURED; CYCLIC AMP; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; FREUND'S ADJUVANT; GANGLIA, SPINAL; HUMANS; HYPERALGESIA; MALE; MOLECULAR STRUCTURE; NEURONS; PAIN; PAIN THRESHOLD; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, PROSTAGLANDIN E; SULFONAMIDES; TIME FACTORS; TRANSFECTION;

EID: 34547097777     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.122010     Document Type: Article

References (36)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br J Pharmacol 14:48-58.
2. Bing RJ and Lomnicka M (2002) Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events. J Am Coll Cardiol 39:521-522.
3. 2 prostanoid receptor subtypes. Eur J Pharmacol 340:227-241.
4. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, Lawson JA, and FitzGerald GA (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296:539-541.
5. 50) of an enzyme action. Biochem Pharmacol 22:3099-3108.
6. Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A, and Sheldrick RL (1994a) A novel inhibitory prostanoid receptor in piglet saphenous vein. Prostaglandins 47:151-168.
7. Coleman RA, Smith WL, and Narumiya S (1994b) International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205-229.
8. Dannhardt G and Kiefer W (2001) Cyclooxygenase inhibitors-current status and future prospects. Eur J Med Chem 36:109-126.
9. 2+ dependent process. Prostaglandins 18:179-190.
10. Garland A, Jordan JE, Necheles J, Alger LE, Scully MM, Miller RJ, and Ray DW (1995) Hypertonicity, but not hypothermia, elicits substance P release from rat C-fiber neurons in primary culture. J Clin Invest 95:2359-2366.
11. Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, and Ray WA (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365:475-481.
12. Hinz B and Brune K (2002) Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 300:367-375.
13. Kimura E, Bersani-Amado CA, Sudo LS, Santos RJ, and Oga S (1997) Pharmacokinetic profile of piroxicam β-cyclodextrin, in rat plasma and lymph. Gen Pharmacol 28:695-698.
14. 2-mediated stimulation of renal sensory nerves. Am J Physiol 287:F1269-F1282.
15. Lenzer J (2005) FDA advisers warn: COX 2 inhibitors increase risk of heart attack and stroke. BMJ 330:440.
16. 4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp Ther 319:1096-1103.
17. 2. Mol Pharmacol 60:36-41.
18. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, and FitzGerald GA (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96:272-277.
19. 3 receptor knockout mice. Br J Pharmacol 133:438-444.
20. 2 to mice. Br J Pharmacol 112:735-740.
21. Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, and Tominaga M (2005) Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 1:3.
22. Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamasaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, et al. (1997) Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388:678-682.
23. Nakayama Y, Omote K, and Namiki A (2002) Role of prostaglandin receptor EP1 in the spinal dorsal horn in carrageenan-induced inflammatory pain. Anesthesiology 97:1254-1262.
24. Nasrallah R and Hebert RL (2005) Prostacyclin signaling in the kidney: implications for health and disease. Am J Physiol 289:F235-F246.
25. Oida H, Namba T, Sugimoto Y, Ushikubi F, Ohishi H, Ichikawa A, and Narumiya S (1995) In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs. Br J Pharmacol 116:2828-2837.
26. Omote K, Kawamata T, Nakayama Y, Kawamata M, Hazama K, and Namiki A (2001) The effects of peripheral administration of a novel selective antagonist for prostaglandin E receptor subtype EP(1), ONO-8711, in a rat model of postoperative pain. Anesth Analg 92:233-238.
27. 2 subtype. J Clin Invest 115:673-679.
28. 2 receptor (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 124:18-25.
29. Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, and Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352:1071-1080.
30. 2-induced cAMP production and sensitization of sensory neurons. J Biol Chem 276:16083-16091.
31. 2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 107:325-331.
32. 4) in bone resorption: an analysis using specific agonists for the respective EPs. Endocrinology 141:1554-1559.
33. Ueno A, Matsumoto H, Naraba H, Ikeda Y, Ushikubi F, Matsuoka T, Narumiya S, Sugimoto Y, Ichikawa A, and Oh-ishi S (2001) Major roles of prostanoid receptors IP and EP(3) in endotoxin-induced enhancement of pain perception. Biochem Pharmacol 62:157-160.
34. 4 receptor antagonist. Br J Pharmacol 148:326-339.
35. 2 receptor subtypes in regulating adenylyl cyclase activity in cultured rat dorsal root ganglion cells. Eur J Pharmacol 535:69-77.
36. 2 production. J Pharmacol Exp Ther 283:1069-1075.